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Abstract 
 
In the last decade, tremendous progress has been made in generating insulin-producing cells 
from both mouse and human pluripotent stem cells. Following the principles that guide 
pancreas embryonic development is a common aspect in all differentiation protocols with 
considerable success in generating β-like cells in vitro. Greatest outcome of the refined 
protocols became apparent in the first clinical trial, recently announced by the ViaCyte 
Company. ViaCyte strategy is based on the implantation of pancreatic progenitors that would 
further mature into functional insulin-producing cells inside the patient body. In this review we 
will discuss the state-of-art in β-cell replacement therapies based on the differentiation of 
embryonic stem cells into glucose-response and insulin-producing cells in a dish. We will also 
discuss alternative approaches to obtain new sources of insulin-producing cells by enhancing 
the regeneration of the endogenous β-cell mass. 
 
 
1. Introduction  
 
Fifteen years ago (November 1999) our group was the first to publish that insulin producing 
cells may be derived from mouse embryonic stem cells (mESC) and able to normalize blood 
glucose in a toxic model of diabetes 
1
. On October 29, 2014, the company ViaCyte (San Diego, 
California) announced the first-in-the-world implant of one type 1 diabetic patient with 
precursor insulin-producing cells derived from human embryonic stem cells (hESC) 
2
. In the last 
twelve months, three studies have come out describing efficient methods to obtain insulin-
producing cells from human embryonic stem cells 
3-5
. How far have we come along in reaching 
an effective treatment for type 1 diabetes mellitus (T1DM)? 
 
A scheme of the main contributors to the development of new strategies to generate insulin-
producing cells derived from either mice or human embryonic stem cell over the past 15 years 
is depicted in Figure 1. Gene trapping and directed differentiation methods 
1, 6, 7
 result in cells 
that contain insulin, express functional markers of the glucose-sensor (eg. glucose blockade of 
KATP channels), the exocytotic machinery and insulin gene expression, processing and storage. 
Progenitors selected by gene-trapping of Nkx6.1 follow maturation after the transplantation 
under the mouse kidney capsule and display dose-dependent effects
8
. Whilst 1 million cells 
transiently normalize blood glucose (3-4 days), 5 million cells produce a more permanent 
effect.  In contrast with coaxial methods, other groups succeeded by growth inhibition 
9
 or 
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 2 
overexpression of Pax4 
10
. Several reviews describe in detail the results of this period 
7, 11-13
, in 
which some of the strategies were based in pancreas development (eg. inhibition of sonic 
hedgehog 
6
), whilst others were more empirical (nicotinamide or butirate). It was also clear 
from the very beginning 
11
 that in order to translate this mouse knowledge to human 
embryonic stem cells we would need to faithfully recapitulate the mammalian developmental 
program.  Unfortunately, at that time human embryonic stem cells were not made freely 
available by the two companies that developed the first lines; Geron in the USA and ESI in 
Singapore and Australia which imposed very restrictive Material Transfer Agreements. In order 
to circumvent tight legislative restrictions imposed by Spain and pursue our work on human 
embryonic stem cells, one of us (Bernat Soria) accepted a Visiting Professorship at the National 
University of Singapore (from 2002 to 2004) to use the ESI owned human ESC in collaboration 
with Profs Alan Colman and Sir Roy Y Calne. Although great strives of progress were achieved 
Confidentiality Agreements signed with ESI limited dissemination of the work. In 2004, the 
social democrate government of the Region of Andalusia rectified the law offering the 
opportunity to develop stem cell work in Granada (National Stem Cell Bank) and Seville 
(CABIMER). In this context, we contributed along with the USA and Sweden to the 
development of new human ESC lines (HVR1, HVR2 and HVR3). Incidentally, between 2007 and 
2009 one of us (BS) was sworn in as Minister of Health of Spain with a mission to rectify the 
archaic Spanish law on human embryonic stem cells. Interestingly, a recent resolution of the 
European Patent Office restrict patenting of results obtained using human embryo derived 
cells, but not on induced pluripotent stem cells (iPSC). 
 
Strategies for in-vitro differentiation of human embryonic stem cells succeeded in better 
reproducing the transcription factors time-course observed for mammalian pancreas 
development 
14, 15
. The seminal work of the group of D’Amour (Novocell-Viacyte) 
16
 established 
some of the key strategies to by-pass the step from ESC to definitive endoderm.  Explained 
below is the work of different groups that drive the long-road to a tentatively non-return 
point, the implantation of the first patient with beta cell progenitors that may mature inside 
the patient body and, eventually, control blood glucose. 
 
------------------ Figure 1 near here ------------------ 
Diabetes describes a group of conditions in which blood glucose is not properly regulated. 
Diabetes mellitus occurs when β-cells fail to secrete the insulin necessary to maintain the 
homeostasis of glucose in the blood flow. Most common forms of diabetes are type 1 and type 
2 diabetes mellitus. Type 1 results from a cellular-mediated autoimmune destruction of β-cells, 
whilst in type 2 diabetes mellitus, insulin resistance from peripheral organs is coupled with 
insulin deficiency resulting from an insufficient β-cell mass or function. Other forms of diabetes 
include gestational diabetes (glucose intolerance during pregnancy) and monogenic forms, in 
which mutations in key pancreatic genes are found (for example in Glucokinase, Pdx1, etc).  
Over time, diabetes can lead to the rise of different long-term complications such as 
retinopathy, neuropathy, nephropathy, critical ischaemia of the limbs and other complications. 
Nowadays, the treatment for diabetes consists in exogenous insulin supply or pancreas/islet 
transplantation, but the inability to achieve a tight control of glucose regulation by exogenous 
insulin administration and the shortage of pancreatic islets donors have motivated recent 
efforts to develop renewable sources of β-cell replacement tissue.  
 
- Why do we need insulin-producing cells?  
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 3 
Pancreatic islet hormones secreted by β-cells in the islets of Langerhans regulate blood glucose 
levels in adult mammals. These “micro-organs” represent 1-2% of the pancreas and contain 
several different cell types, including endocrine cells, endothelial cells, and nerve terminals. 
Pancreatic β-cells, which in humans represent around 50% of the islet mass, synthesize, store, 
and release insulin in response to nutrients, while α-cells (40%) secrete glucagon and δ-cells 
(10%) produce somatostatin.  
 
The metabolic interbalance, resulting in blood glucose homeostasis is governed by several 
hyperglycemic factors (glucacon, growth hormone, glucocorticosteroids, epinephrine) and only 
one hypoglycemic agonist (insulin). This is the reason why loss of pancreatic β-cells, 
responsible of the synthesis, storage and release of insulin produces a life threatening disease: 
diabetes (from the greek “pass through”). High blood glucose saturates renal tubule glucose 
transporters and glucose appears in urine (glucosuria), the resulting osmotic pressure increase 
inside the kidney tubules augment urine formation (polyuria) and then patients need to 
increase liquid intake (polydipsia). Since insulin is needed for glucose to enter into the cells, 
storage of energy (fat, glycogen) decreases and as a consequence type 1 diabetic patients 
loose weight. Before the discovery of insulin in the 1920’s 
17
, type 1 diabetes was an acute and 
lethal disease. Exogenous insulin administration (first purified from porcine and bovine 
pancreas and later obtained by recombinant methods) allowed blood glucose control but only 
intensive insulin therapy diminished diabetic complications (retinopathy, nephropathy, 
myocardial infarction, stroke, diabetic foot, etc), unfortunately with an increased risk for 
hypoglycemia.  In terms of blood glucose regulation pancreatic islets located in the portal 
vascular bed will do the job better than any option. This is the reason why islets are 
transplanted into the liver (direct implantation into the exocrine pancreas is not considered 
because of the risk of pancreatitis).  However, islet transplantation as a potential cure for 
diabetes is limited by scarcity of donors, suboptimal islet procurement techniques and the side 
effects of long-term immunosuppressive therapy. 
 
Glucose-induced insulin release needs a glucose-sensing mechanism (the “glucose-sensor”), a 
response element (the “exocytotic machinery”) and a regulated gene expression, processing 
and storage of insulin (transcription factors, miRNAs, Golgi apparatus, secretory granules) 
(Figure 2). Although pancreatic β-cells share many properties with peptide secretory nerve 
terminals, some of the mechanisms are unique for the β-cell. Glucose-sensing mechanisms 
need a high capacity low affinity glucose transporter (Glut-2) that equilibrates glucose 
concentration at both sides of the plasma membrane, a kinase that works at physiological 
blood glucose concentrations (hexokinase IV or glucokinase) and a potassium channel, which is 
blocked by the ATP and diadenosine polyphosphates formed during glucose metabolism (ATP-
dependent K-channels). Additionally, β-cells in order to sense glucose lack the Pasteur effect, 
then glucose degradation is not stopped by augmentation of the ATP/ADP ratio, which in turn 
increases ROS formation with subsequent β-cell damage. Exocytosis is initiated by the 
blockade of ATP-dependent K-channels depolarizing the β-cell, opening voltage-activated Ca
2+
 
channels and increasing Ca
2+
 in the submembrane region 
18
 creating a [Ca
2+
]i code that do not 
desensitize and correlates with insulin secretion. Pancreatic β-cells initiate an oscillatory and 
widespread bursting activity throughout the whole islet due to the gap-junction conductance 
oscillations 
19, 20
. Ca
2+
-sensing proteins of the exocytotic machinery promote the fusion of the 
granule with the membrane and release insulin to the extracellular space. All these “fast” 
effects of glucose on the β-cell operate, provided that β-cells are ready to be stimulated. 
Insulin gene expression is finely tuned by nutrients as is processing in the Golgi apparatus and 
storage in secretory granules (together with C-peptide and Zn
2+
). In contrast with the detailed 
study of the transcription factors involved (PDX1, Nkx6.1, CREB, etc), the biophysical processes 
governing these “slow” regulatory effects of glucose have been less studied 
21
. Glucose is 
considered to be an “initiator” of insulin release, whilst other metabolic signals (amino acids) 
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 4 
or neural and paracrine factors (acetylcholine, colecystokinin), are unable to induce insulin 
release by their own, and rather “potentiate” the effect of glucose using mainly the release of 
Ca
2+ 
by intracellular stores.  
 
------------------ Figure 2, near here ------------------ 
 
In summary, a long list of proteins (transporters, ion channels, connexins, [Ca
2+
]i sensors, etc) 
are needed for glucose sensing and insulin release. Furthermore, another long-list of 
transcriptions factors and miRNAs, regulate insulin gene expression and processing.  A proper 
characterization and identification of a surrogate β-cells should not only identify the presence 
of these components but also their ability to work and respond to glucose (initiator of insulin 
release) and to potentiate -agonists- the effect of glucose (potentiators), and thus, to 
normalize blood glucose levels in diabetic animal models. 
 
2.  From ESC to Insulin-producing cells: The challenge of making a β-cell 
 
Stem cells are non-specialized clonogenic cells defined by two important characteristics: self -
renewal and pluripotency. These paradigmatic properties depend on transcription factors 
(Nanog, Oct4, etc), ion channel activity 
21, 22
 and cell-to-cell communication 
23
. Proliferation will 
permit the expansion of millions of cells from a native undifferentiated cell. In terms of 
functional substitution in type 1 diabetes an estimate of 10
9
 β-cells are needed to control 
blood glucose in an adult. Subsequent changes in cellular phenotype may be transiently 
reversible 
24
, however epigenetic modifications driving cell lineage differentiation may 
permanently lock the new entity into an adult post-mitotic cell or a committed progenitor. In 
terms of proliferation and differentiation capabilities embryonic stem cells are the most 
attractive, then multiple efforts reported multistep differentiation procedures, which end with 
insulin-producing cells, therefore, the human embryonic stem cells hold the promise of an un-
limited, but allogenic, source of cells for this propose. On the other hand, the discovery of the 
induced pluripotent cells (iPSC) by Yamanaka’s team 
25
 made possible the use of patient own-
cells and in both cases to build a bank of HLA compatible cells.  
 
After the proof-of-concept was established in rodent 
1
 and human 
26
 ESCs, more than one 
hundred papers reported the conversion of different stem cells and progenitors into insulin-
producing cells either from monocytes 
27
, hematopoietic stem cells or mesenchymal stromal 
cells 
28
. Transdifferentiation from the three germ layers into insulin-producing cells exceeds 
the aim of this review. Here we will discuss the consolidated knowledge using mammalian 
embryonic stem cells as well as innovative concept of islet cell regeneration giving support to a 
new era in the treatment of diabetes mellitus. 
 
a. Lessons learned from islet development 
 
The current success in generating pancreatic cell lineages from human ESCs relies on 
recapitulating the key events that regulate pancreatic lineage commitment in the embryo. The 
advances in our understanding of the key transcription factors and signaling pathways that 
govern pancreas development and β-cell formation have been crucial for the design of new 
protocols for generation of in vitro insulin-producing cells from ESCs. Our knowledge of human 
pancreas development derived largely from animal models, such as rats, chicks, fish and 
mainly mice, and it is based on the assumption that the molecular and cellular aspects of 
pancreas development are conserved, although some aspects of the mouse ESCs 
differentiation protocols may differ from those applied to human ESCs differentiation 
protocols. 
 
Page 4 of 34
URL: http://mc.manuscriptcentral.com/eobt  Email: Lizzie.Howard@informa.com
Expert Opinion On Biological Therapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 5 
Tremendous progress has been made in the field of pancreas development and it has been 
extensively reviewed 
29, 30
. In this review, we will focus on the main transcription factors that 
govern different stages of islet development and β-cell fate.  
 
- Pancreas Organogenesis and Islet Development 
After gastrulation, the definitive endoderm is specified by the expression of endodermal 
markers including FoxA2, Sox17 and GATA4 and GATA6 transcription factors 
31-33
. The 
development of this germ layer involves highly orchestrated morphogenetic events, reciprocal 
interactions with the adjacent mesoderm and ectoderm, and cell determination and 
differentiation 
34-38
.  The result of these patterning events is a gut tube in which budding 
organs are defined in determined regions along the tube 
39
. Each stage of pancreas 
development is achieved by combinatorial of signals that activate in a specific spatial and 
temporal way a set of transcription factors. The region of the gut tube that will acquire a 
pancreatic fate requires retinoic acid signal and the exclusion of both Sonic hedgehog (Shh) 
and Bone Morphogenic Proteins (BMPs) 
40-43
. The combined actions of activation and inhibition 
of these signaling pathways will result in the expression of Pdx1, Ptf1a, Sox9 and Nkx6.1, which 
are known as multipotent pancreatic progenitor markers 
44, 45
. The homedomain transcription 
factor PDX1 is one of the first markers of the developing pancreas. Lack of PDX1 function leads 
to pancreatic agenesis in mouse and mutations in human PDX1 are associated to hypoplastic 
or absence of pancreatic tissue, indicating the importance of this transcription factor in 
pancreas development 
45-47
. Similarly, mutations in PTF1a also have been linked to pancreatic 
agenesis in both mice and humans 
48, 49
. More recently, genomic sequencing of neonatal 
diabetes patients associated to pancreas agenesis has revealed a new gene responsible for this 
pancreatic disease, GATA6 
50
. Studies in mice have shown that GATA4 and GATA6 are required 
to maintain the number and identity of pancreatic progenitor pool to allow the normal 
progression of pancreas development 
51, 52
. 
 
Around embryonic stage (e) 9.5 in the mouse, epithelial buds undergo branching 
morphogenesis invading the surrounding mesenchyme resulting in the formation of small 
ductules, which contain the precursor cells of the acini, ducts, and islets of Langerhans 
53
. The 
most important of the transcription factors that have been identified as specific for endocrine 
development is the bHLH transcription factor Neurogenin3 (Ngn3). Ngn3 expression is first 
observed at e9.5 in the mouse, and its expression peaks around e15.5, a stage that 
corresponds to the endocrine differentiation wave 
54-56
. Lineage tracing experiments have 
shown that Ngn3 expressing-cells (Ngn3
+
) function as endocrine precursor cells and give rise to 
all hormone-secreting pancreatic cells; α (glucagon-secreting), β (insulin-secreting), δ 
(somatostatin-secreting), PP (pancreatic peptide-producing) and ε (ghrelin-secreting) cells 57. 
That observation agrees with the phenotype of Ngn3 knockout mice, which lack all endocrine 
cells types 
58
. Ngn3-positive cells undergoe dynamic changes in gene expression, resulting in 
the activation of Ngn3 targets (Pax4, Arx4, Rfx6, NeuroD1, Pax6, Isl1) 
59, 60
.  
 
The hormone-expressing cells become apparent around e13.5. By this time, the gut tube 
rotates to bring both buds into proximity and dramatic changes occur in the cellular 
architecture of the pancreas. Similarly, a rapid branching morphogenesis and acinar cell 
differentiation occurs 
53
. There is a major amplification of endocrine cell numbers, mainly β-
cells, which organize into islets clusters. Choice between α- and β-cells fate rely on the mutual 
repression of lineage-specific transcription factors. The transcription factor Pax4, Pdx1 and 
Nkx6.1 are critical for β-cell commitment, whereas Arx4 determines α-cell fate 
61-65
.  
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 6 
In addition to its role in early pancreas development discussed above, Pdx1 is expressed in β-
cells at later stages of pancreas development and persist in the adult life. Its activity is required 
to activate important genes for β-cells function, including Glut2 and Glucokinase 
66-68
.  Cell 
maturity is also achieved by the cooperation of MafA and NeuroD and Pdx1 in the 
transcriptional activation of the Insulin gene 
69-71
. 
 
b. In-vitro differentiation 
 
As mentioned before, the common approach to differentiate human embryonic stem cells and 
human induced pluripotent cells towards β-cells is based on a multi-stages protocol 
attempting to reproduce in vivo pancreas development. Protocols aim to induce hESCs and 
hiPS to follow a sequential transition through mesendoderm, definitive endoderm, gut-tube 
endoderm, pancreatic endoderm and endocrine precursor stages, to finally obtaining 
functional insulin-expressing cells 
3-5, 72
. Reported signaling pathways and factors required to 
direct pluripotent stem cells differentiation towards functional insulin-secreting cells are the 
result of years of investigation. However, due to the complexity of the aim, a highly efficient 
step-wise differentiation protocol is still missing. 
 
The major problems in directing hESCs and iPS differentiation to β-cell-like cells are: 
• The low reproducibility of the current differentiation protocols and  
• The low amount of insulin-secreting cells produced at the end of the 
differentiation processes, which indicates that we are still far away from 
obtaining an optimal β-cell mass (1x10
9
 cells) that could be used for cell therapy.  
Protocols described so far generate PDX1 and/or insulin positive cells, which need further 
maturation when transplanted into immunocompromised mice 
73-75
. 
 
------------------ Figure 3 near here ------------------ 
 
- Obtaining definitive endoderm 
 
In order to drive human ESCs differentiation towards insulin producing cells, the first goal is 
the efficiently generate definitive endoderm, which is the first step towards commitment into 
pancreatic fate. Whereas Activin A and Wnt activators are commonly used for DE induction, 
Noggin supplementation is justified by the requirement for low BMP signalling to direct the 
mesendoderm towards anterior primitive streak derivatives 
16, 76, 77
.  This first step of 
differentiation has been readily achieved by D’Amour et al. 
16
 using a combination of TGFβ 
family member, Activin A, to activate Nodal signaling, and low serum concentration of media 
to avoid the activation of PI3K. Furthermore, to improve the yield of definitive endoderm cells, 
the activity of PI3K could be inhibited using two different inhibitors, LY 294002 or wortmannin. 
Wnt3a-mediated Brachyury expression is also important for the migration of precursors cells 
through the anterior region of the primitive streak (PS) and the formation of a mesendoderm 
population from which both endoderm and mesoderm will generate depending on the 
magnitude and duration of Nodal signalling. Hence, the efficiency of definitive endoderm 
generation further improve with exposure of human ESCs to a combination of Activin A and 
Wint3a in the absence of serum on the first day, followed by one day of culture in medium 
supplemented with Activin A and 0,2% of serum and 3 days in medium supplemented with 
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 7 
Activin A and 2% of serum 
26
. In contrast to Wnts, BMPs inhibit endoderm induction. 
Therefore, inhibition of BMP signalling using the BMP antagonist, Noggin, resulted in increased 
expression of PS/endoderm markers and in a rapid reduced expression of PS/mesoderm 
markers, thus demonstrating the cooperatively intertalk of canonical Wnt/β-catenin, 
Activin/Nodal and BMP signaling pathways during ESCs specification of PS, mesoderm and 
endoderm 
76
. A different approach to induce definitive endoderm has been recently published 
78
, consisting in the use of two small molecules identified as endoderm inducers (IDE1 and 
IDE2) with efficiency similar to that obtained with Activin A treatment. 
 
- Pancreatic progenitors and late maturation 
 
Maturating endocrine precursors toward specialized and functional hormone-secreting cells is 
still the most problematic step to direct pluripotent stem cells differentiation to insulin-
producing cells 
79, 80
. Despite the great number of biologically active compounds that have 
been already tested for this purpose, none of them has successfully worked 
81, 82
. D’Amour et 
al. 
26
 used a mix of different “maturation factors” such as IGF1, Exendin-4, HGF and B27 
supplement during terminal differentiation stages, but observed only minor effects on 
differentiation when these factors were omitted. On the other hand Cho et al. 
83
 demonstrated 
that the application of betacellulin and nicotinamide to D’Amour’s protocol resulted in 
sustained Pdx1 expression and led to subsequent insulin production. Nevertheless, cells 
obtained from in vitro differentiation strategies are not mature enough to be completely 
functional; although they express different markers of β-cells, such as insulin, GLUT2 or 
Glucokinase (GK), they display functional defects in the glucose sensing pathway or the 
exocytotic machinery 
84-87
. Hence, strategies to improve the in vitro maturation process of 
endocrine precursors are needed and until quite recently has been achieved 
3-5
.   
 
 
- Other approches to take into account for maturation 
 
All strategies describe so far for pluripotent stem cells differentiation to obtain functional 
insulin secreting cells are the result of a decade of research and the fact that it has not been 
still achieved demonstrate the complexity of reaching this aim. New factors and different 
culture conditions are mandatory to induce a complete differentiation and maturation of 
pluripotent stem cells-derived β-cells. Here we mention some novel approaches that could be 
useful to improve definitive endoderm generation and final maturation of the endocrine 
precursors, resulting in a more efficient insulin-secreting cells differentiation strategy, below 
some of these strategies are overviewed. 
 
i. Effects of soluble factors in the maturation process 
 
Screening for new active molecules to be used as “maturation factors” could be helpful. In this 
context, a previous study described fetal soluble factor, released by pancreatic buds, that has 
been used to induce in vitro endocrine pancreatic differentiation from mouse ESCs 
7
. 
Subsequent proteomic studies (unpublished data) have demonstrated that one of the most 
abundant proteins present in the soluble factors released by pancreatic buds was 
Regenerating 1 (Reg-1). Reg-1 is normally induced in pancreatic β-cells and acts as an 
autocrine/paracrine growth factor for β-cell regeneration 
88, 89
. Based on this information, Reg-
1 could be used in differentiation protocols to induce human ESCs-derived β-cells maturation.  
 
ii. Nitric oxide and definitive endoderm induction 
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 8 
The relevant role of Nitric Oxide (NO) in developmental processes in the embryo has been 
previously described 
90, 91
, including the induction of ESCs differentiation into cardiomyocytes 
92, 93
. Short time exposure of ESCs to exogenous donors of NO like diethylenetriamine/nitric 
oxide (DETA-NO) induces early differentiation towards a definitive endoderm phenotype. 
Treatment of ESCs with DETA-NO for only 19h induces the expression of endodermal markers 
Pdx1 and GATA4, which represents an attractive alternative to the classical treatment with 
Activin/Wnt3a for 3-5 days to direct the cells towards a endodermal fate 
24, 94
. During 
pluripotent stem cells differentiation, lineage commitment is controlled not only by a gamut of 
transcription factors and soluble factors, but also by epigenetic events 
24, 95
. In this regard, NO, 
which is a messenger molecule involved in a wide variety of pathophysiological processes, has 
been shown to have a direct effect on gene expression through epigenetic events 
24, 96
. The link 
between NO-dependent early stem cells differentiation and its epigenetic effects opens a new 
field of investigation aimed at defining the possibility to ex vivo prime stem cells with NO 
donors and/or more classical epigenetic drugs as a strategy to obtain specialized cell 
populations.  
 
iii. Micro-RNAs 
 
Emerging evidence indicates that micro-RNAs (miRs) a group of small non-coding RNAs are 
prime candidates to fine-tune signaling pathways and gene expression and therefore able to 
control a variety of physiological processes, including glucose homeostasis 
97
. Several miRs are 
expressed at high levels during human pancreatic islet development and are known to have a 
functional role in pancreatic β-cell development and function. Among the pancreatic miRs 
identified, miR-15a has been shown to induce insulin biosynthesis by inhibiting UCP-2 gene 
expression 
98
. miR-30d has an important role in the regulation of insulin gene transcription by 
glucose through negative regulators of insulin gene expression 
99
. miR-124a regulates Foxa2 
gene expression and preproinsulin 
100
. miR-9 is a key factor in the modulation of Sirt1 
expression, and therefore modulates insulin secretion because by regulating exocytosis 
101
. 
overexpression of miR-373 leads to differentiation towards the mesendodermal lineage 
102
, 
miR-148 involved in regulating insulin synthesis via upregulation of insulin transcription 
103
, 
miR-375 has been implicated not only in pancreatic islet development but also in mature islet 
function because is required for normal glucose homeostasis 
104, 105
, miR-7 is the most 
abundant endocrine miR and is expressed at high levels also during human pancreatic islet 
development 
106
, and inhibition of miR-7 results in decreased β-cell numbers and glucose 
intolerance in the postnatal period 
107
. Previous studies have shown that overexpression of 
miR-375 promotes differentiation of ESCs to pancreatic endocrine, and provide evidence that 
constitutive miR-375 expression in ESCs led to the expression of beta cell markers as well as 
the production of insulin in reponse to glucose in islet-like clusters 
108
. Furthermore, expression 
of miR-7 in human fetal pancreas increase at weeks 14-18 that correspond to induction of 
PDX-1 and other genes required for endocrine cells fate specification 
107
. Altogether suggests a 
novel mechanism in the control of endocrine cell differentiation and consequentially miR-7 
could be considered as an important player for the achievement of a complete differentiated 
human pluripotent stem cells-derived β-cells. The mechanisms by which miRs regulate this 
process remain poorly understood.  
 
- Recent achievements 
 
As previously mentioned, insulin-producing cells obtained by numerous in vitro differentiation 
protocols published so far are commonly immature and non-functionally glucose-responsive. 
As a consequence, many research groups omitted the late in vitro differentiation steps, and 
allowed pancreatic progenitors to specialize into functional β-cells by in vivo maturation after 
transplantation in STZ-induced hyperglycaemic mice 
5, 73-75, 109
 or included small molecules and 
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 9 
growth factors to medium formulation in the last stage of cell differentiation. IGF1, Exendin-4, 
HGF and B27-supplement were used as a “maturation factors” during late differentiation 
stages, but only minor effects were observed 
26
, fibronectin and insulin-transferrin-selenium 
(ITS) were successfully used during the suspension culture step 
110
, and recently, R428 (a 
selective small-molecule inhibitor of the tyrosine kinase receptor AXL), Alk5 receptor inhibitor 
(Alk5i), N-acetyl cysteine (N-Cys) and thyroid hormone T3 were successfully used to come up 
with highly differentiated cells quite similar to mature β-cells 
3-5
. 
 
i. Impact of Resveratrol on stem cells-derived endocrine precursors maduration: 
 
Several studies reported the beneficial impact of resveratrol (RSV) on insulin secretion and 
how this compound potentiates glucose-stimulated insulin secretion (GSIS), not only in rat 
insulinoma cell lines (INS-1E), but also in isolated human islets 
111
. Based on this knowledge, we 
investigated whether RSV could improve the final maturation step of hESCs differentiation 
towards β-cells. RSV (3,5,4'-trihydroxy-trans-stilbene) is a polyphenol that has been shown to 
activate SIRT1, a NAD
+
-dependent sirtuins or class III histone deacetylase (HDACs) 
112, 113
. We 
have shown that SIRT1 contributes to the establishment of specific 
developmental/differentiation programs of hESCs 
114
. SIRT1 in combination with antagonists 
(nicotinamide) 
1, 83, 127
 promotes stem cells differentiation and in combination with agonists 
(RSV) 
4
 promotes maturation. Other studies demonstrated the effect of RSV on insulin 
secretion using INS-1E and human islet 
111, 115
. SIRT1 represses mitochondrial uncoupling 
protein-2 (Ucp2) transcription by binding directly to its promoter 
116
 resulting in increased ATP 
production and insulin secretion in INS-1E and in BESTO mice islets 
117, 118
. Additionally, RSV 
induced an up-regulation of key genes for β-cell function such as Pdx1, Glut2, Gk, Hnf1α and 
Tfam in both INS-1E cells and human islets 
111
, this up-regulation has been described as a 
possible mechanism by which RSV potentiates metabolism-secretion coupling in β-cells and 
interestingly for the maintenance of the β-cell identity 
119, 120
. We have shown for the first time 
that RSV is a critical compound improving the maturation of hESCs-derived endocrine 
precursors towards insulin-secreting cells, thus proposing its use for a more efficient insulin-
secreting cells differentiation strategy 
4
. 
 
ii. Two independent works, same achievement 
Using high-throughput screening techniques, Kieffer’s team 
5
 improved considerably their 
original protocol, which -for the first time- showed that fully functional beta-like cells could be 
generated in vitro and were able to permanently reverse hyperglycemia when transplanted 
into diabetic mice. It is a seven-stage in vitro differentiation protocol that builds upon 
protocols previously used to specify pancreatic progenitors. The addition of vitamin C at early 
stages of differentiation results in production of PDX1
+
/NKX6.1
+
 pancreatic progenitors with 
low expression of NGN3 and its downstream targets. Further differentiation of pancreatic 
progenitors using a combination of reagents including an ALK5 inhibitor, BMP receptor 
inhibitor and thyroid hormone T3, wich results in the increase of NGN3 expression and a 
substantial fraction of PDX1
+
/NKX6.1
+
/NEUROD1
+
cell populations. The continued exposure to 
ALK5 inhibitor, BMP receptor inhibitor, thyroid hormone T3 and Notch inhibitor results in the 
generation of NKX6.1
+
/insulin
+
 cell populations that express insulin but not glucagon or 
somatostatin. Finally, the screening of a number of additional reagents (a library of >40 small 
molecules and growth factors) identified R428, an inhibitor of AXL, which, in combination with 
ALK5 inhibitor and T3, potently induces MAFA expression in PDX1
+
/NKX6.1
+
/NEUROD1
+
 cells 
that are insulin
+
/glucagon
−
/somatostatin
−
. The resulting highly differentiated cells display key 
characteristics of mature beta cells, including glucose-induced insulin secretion, and rapidly 
reverse diabetes after transplantation in mice. 
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A 70 kg diabetic patient may need about 0,5-1 x 10
9
 insulin-producing cells in order to 
normalize blood glucose. To obtain such a critical mass of pancreatic progenitors committed to 
be differentiated into insulin-producing cells or a similar number of surrogate β-cells, it is 
required to expand the population of pancreatic precursors. Melton's group 
3
 follows a very 
similar protocol to that of Kieffer's, with common elements but slightly simpler, and report a 
strategy for large-scale production of functional human β cells from human pluripotent stem 
cells. By using sequential modulation of multiple signalling pathways in a three-dimensional 
cell culture system, without any transgenes or genetic modification, they succeed to generate 
glucose-responsive, monohormonal insulin-producing cells that show key features of a bona 
fide β-cell, including coexpression of key β-cell markers and ultrastructure. Furthermore, these 
cells mimic the function of human islets both in vitro and in vivo.   
 
The recent success in generating more mature beta cells from human pluripotent stem cells is 
very encouraging and although more basic research is needed, the field has taken important 
steps towards using human pluripotent stem cells-derived β-cells in cell therapy in diabetes 
3-5
. 
Actually, the first and generally accepted initiative of obtaining pluripotent stem cells-based 
therapy is that headed by ViaCyte Inc. Looking ahead, it is likely that phase 1 clinical trials 
based on using insulin-producing β-cells derived from human pluripotent stem cells, promoted 
by ViaCyte Inc. Company, will soon follow. ViaCyte strategy consists in implanting non-mature 
progenitors that may thereby follow the maturation process inside a device (VC-1) inside 
patient body and follow the maturation process by measuring insulin and human C-peptide 
production in parallel with exogenous needs for blood glucose regulation. 
------------------ Figure 4 near here ------------------ 
 
3. Cell selection strategies 
 
In-vitro directed differentiation methods have been successfully applied to generate hESC-
derived β-cells and β-progenitor cells. However, many of these methods yield different islet-
like cell enrichment. Thus, independently of the percentage of cells, which are positive for 
human C-peptide (20 to 60%), Pdx-1 (aprox 100%) and other markers, currently, there is not a 
single method that generates a completely pure post-mitotic human ESC-derived β-like cell 
culture. This generates several problems: i) it is important to enrich first the population of 
differentiated cells and then they could be expanded and ii) the risk for undifferentiated cells 
inducing teratoma formation exists 
73, 121
. Thus, without a well-designed method of selection of 
tissue-specific precursors, the cells obtained after the different differentiation protocols are 
not yet scalable for clinical application. 
 
A variety of methods could be used or have been developed to select islet-cell differentiated 
cells. For example, the uses of lineage-specific cell surface markers. In the case of β-cells it 
would be the glucose transporter 2 (Glut-2), that it is expressed in the cellular membrane of β-
cells 
122
. However, Glut-2 could not be enough specific because is also expressed in the liver 
123
 
also coming from endoderm. Another authors 
124
 were able to enrich pancreatic endoderm 
cells and endocrine cells, derived from hES cells, by using CD142, CD200 and CD318 cell-
surface markers.  Nowadays, there are still large gaps in our ability to select islet-cell 
differentiated cells on the basis of surface marker expression. In addition, the use of 
fluorescent reporters of gene expression has been used as an approach to select differentiated 
islet-cells. Then, the differentiated cells can be selected by using fluorescent-activated cell 
sorting. In this regard, Shiraki et al. 
125
 were able to select endoderm and Pdx1-positive 
pancreatic progenitors from ES cells. Alternatively, cell-trapping methods using antibiotic 
resistant genes coupled to the insulin gene promoter 
1, 126, 127
 or the Nkx6.1 gene promoter 
6
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has also been used. This technology consists on the use of reporters that activate expression of 
a selectable marker that can drive differentiated islet-cells to almost 100% homogeneity by 
restrictive survival using antibiotics. The generation of reporter lines that carries an eGFP 
reporter gene under the control of insulin or any transcription factor needed for islet-cell 
differentiation, such as Pdx1 is another strategy 
128
 employed. However, random genomic 
integration and unregulated transgene expression are limitations to this approach. To address 
these limitations, homologous recombination to “knock-in” a fluorescent protein into a 
specific genetic locus can be used. Currently there exist hESC reporter lines that have been 
used to sort neuronal 
129
, cardiac precursors 
130
 and β-cell precursors 
131, 132
.  
 
Actually, new alternatives to avoid the use of genetically modified stem cell lines for isolating 
tissue-specific progenitors are being explored. In this regard, King et al. 
133
 modified dual-
fluorescence resonance energy transfer (FRET) “molecular beacon” technology, using 
fluorescence-activated cell sorting (FACS). This new technology allows the isolation of live 
differentiated ESCs based on expression of intracellular proteins and leaving the stem cell 
genome intact. 
 
In conclusion, the ability to select specific differentiated stem cells with tissue-specific 
properties is a key aspect that will need to be overcome for clinical application of stem cells. 
 
- Role of non β-cell partners:  
 
Intra-islet interactions have shown that β-cells act as a functional syncytium and that other 
endocrine (alfa-, delta- and PP-cells) and non-endocrine (endothelial) cells play a relevant role 
in the construction of an integrated response to nutrient signals. Although isolated β-cells keep 
the whole machinery to respond to nutrients, its efficiency increases substantially when 
couples other β-cells 
134
. Minimal size aggregates that better mimic islet behavior were 
estimated in 10-15 β-cells. More recently, a role for α-cells has been reported 
135
.  
 
Moreover successful engraftment may be improved by cotransplantation of mesenchymal 
stromal cells that will also protect from immune attack (ESC and banks of HLA compatible cells 
are allogenic in nature). 
 
This new approach is be based on the ability of MSCs to secrete many cytokines and growth 
factors  that both provide an in vivo favorable microenvironment supporting engrafment of 
insulin-producing cells, angiogenesis and immunomodulation  
 
Renewal of β-cells may depend on replication of differentiated β-cells and/or ductal 
progenitors, then it is tempting to speculate that an in-vitro obtained progenitor of ductal and 
endocrine cells which differentiate and maturate after implantation may be closer to 
endocrine pancreas repair. Most efforts were focused on the post-mitotic β-cell whilst, in 
theory, a ductal-endocrine progenitor will be better in order to keep tissue homeostasis. Then, 
efforts to better control developmental decisions ending with ductal, endocrine or exocrine in-
vitro differentiation 
136
 are needed. 
 
 
4. Minimal standards to accept a β-cell surrogate  
 
  
As described above a pancreatic β-cell gathers together three main features: glucose-sensing, 
exocytotic machinery and insulin gene expression, processing and storage complexes. Whilst 
early and late progenitors could be better characterized the transcription factors governing the 
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process (Figure 3) to characterize a postmitotic β-cell we should test the presence and 
function of the 3 complexes. Tables I and II summarize these in insulin-producing cells derived 
from mouse and human embryonic stem cells. The aim is not a full descriptive report but a 
summary of the breakthrough published papers with an historical perspective, which drive this 
research.  
 
Tables I and II 
 
 
5. From adult progenitors to Insulin producing cells 
 
 
a. Defining the Holy Grail of Islet Re-Juvenescence 
 
In recent years, the concept of β-cell regeneration has come into the limelight as a potential 
complementary approach to stem cell therapy for future treatment of Type 1 Diabetes 
Mellitus (T1DM) 
137
. These two approaches or not mutually exclusive as on one hand lessons 
learned from in vivo regeneration may aid in the development of improved in vitro 
differentiation protocols while on the hand characterization of novel differentiating genes 
highlighted in in vitro studies may become useful markers to identify a bona fide re-
juvenescence cell source within the pancreas. The notion of regeneration stemmed from 
studies revealing that individuals with long standing T1DM were found to retain a residual and 
functional β-cell mass, which persisted in a steady state turnover within the hostile 
autoimmune environment 
138-140
. In agreement with these human data, studies performed in 
mouse model of experimental autoimmune diabetes, revealed that the immunological 
destruction of islet β-cells was associated with enhanced β-cell regeneration 
141, 142
. Consistent 
with an intimate dialogue between immunity and islets to promote β-cell regeneration, 
immunosuppressive therapy using anti-CD3 monoclonal antibodies impeded β-cell 
replenishment 
141
. These studies highlight a fundamental paradigm, if ever an in vivo 
regenerative approach to treat T1DM is to be implemented: A non-mutually exclusive strategy 
in which the immune response as well as β-cell regeneration and function are exquisitely fine 
tune is essential in order to successfully regain an optimally performing β-cell mass and 
maintain normoglycemia.  
 
Notwithstanding this complex crosstalk that likely triggers the regeneration process, the 
subsequent target cells and mechanisms that leads to β-replenishment remains a matter of 
controversy 
143, 144
. Indeed, depending on the experimental mouse model and degree of injury 
inflicted to the pancreas, new β-cells were shown to be generated by neogenesis of ductal 
epithelium cells 
145, 146
, by trans-differentiation of α- and δ-cells to β-cells 147-150 and from rare 
pancreas-derived multipotent precursor cells 
151, 152
. Interestingly, in young animals trans-
differentiation after extreme β-cell loss was shown to arise from δ-cell conversion while in 
older mice replenishment was predominantly through α-cell trans-differentiation 
147, 148
. These 
findings indicate that islets retain an age-dependent specific cell plasticity challenging the 
current perception that regeneration is gradually lost with age 
153, 154
. Although exocrine acinar 
cells can be reprogramed to insulin-producing cells in vivo via the combined viral mediated 
ectopic expression of PDX1, NGN3 and MAFA 
155
, this conversion does not appear to occur 
spontaneously in either mice or human, excluding these cells as a likely source of in vivo 
regeneration. On the hand, bone marrow stem cells also appear to indirectly contribute to islet 
regeneration by promoting proliferation of resident islet cells 
156, 157
. Alternatively, lineage-
tracing studies demonstrated that pre-existing mouse adult pancreatic β-cells were the major 
source of new insulin-producing cells during adult life and also after pancreatectomy 
158-160
. 
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Furthermore, it was shown that all β-cells could contribute to islet growth and maintenance 161. 
Albeit the compelling evidence that β-cell replication is the main mechanism of β-cell 
regeneration in rodents, neogenesis and trans-differentiation were also reported in pancreas 
of T1DM patients providing the proof-of- concept that all three processes independent of their 
contribution are important for β-cell regeneration 
162-165
. Identifying factors or signals 
regulating these processes potentially triggered and sustained by the autoimmune 
environment will be the key to harnessing a successful in vivo regenerative therapy. 
 
b. Pax4 and Arx, master regulators of β-cell regeneration  
 
Lessons learnt from pancreas development studies have clearly demonstrated an antagonistic 
role of the transcription factors Pax4 and Arx in islet β and α cell faith decision from an early 
Ngn3-positive endocrine progenitor 
166
. High expression levels of Pax4 relative to Arx were 
shown to favor a β-cell phenotype while low levels relative to Arx result in a α cell phenotype 
62
. Seminal work performed by Collombat and colleagues demonstrated that forced expression 
of Pax4 in endocrine precursors as well as in mature α-cells in mice impelled the conversion of 
these cells into insulin-producing cells resulting in enlarge islets. In parallel, a continuous 
replenishment of α-cells was detected through neogenesis of an Ngn3-positive progenitor 
subpopulation located in the ductal epithelium vicinity 
167
. Similarly, the selective inhibition of 
the Arx gene in α-cells through conditional loss-of-function in mice resulted in the efficient 
conversion of adult α-cells into β-like cells at any age 168. More importantly both transgenic 
animal models were rescued from hyperglycemia subsequent to toxin-induced β-cell 
destruction as a result of constant β-cell renewal through α- cell transdifferentiation 167, 168. 
Independently, we demonstrated that conditional overexpression of Pax4 in adult β-cells 
protected transgenic animals against streptozotocin-induced hyperglycemia 
169
. More recently, 
we have also validated this protection in an animal model of experimental autoimmune 
diabetes (manuscript in preparation). Interestingly, long-term expression of Pax4 in vivo also 
resulted in loss of islet insulin secretion with the concomitant appearance of a Pdx1
+
/insulin
-
/BrdU
+
 cell subpopulation suggesting a de-differentiation of β-cells that potentially acquire a 
proliferative phenotype 
169
. Interestingly, these cells are reminiscent of the sub-population 
reported by the group of van der Kooy 
151, 152
. Substantiating this notion, we demonstrated 
using a transgenic mouse model in which EGFP along with the CRE recombinase expression is 
under the transcriptional control of the Pax4 promoter (pPAX4/EGFP-CRE) the existence of a 
Pax4/EGFP-enriched β-cell subpopulation. More importantly, mitogens such as activin A, 
betacellulin and GLP-1 increased Pax4 mRNA levels specifically in EGFP-positive β-cells 
170, 171
. 
These results indicate the potential co-existence of two β-cell subpopulations within islets: A 
predominant Pax4-negative subpopulation which is functionally active in maintaining 
glycaemia and a Pax4-expressing subpopulation prone to proliferation that adapts the β-cell 
mass in response to physiological cues. These studies combined with the work of Collombat 
clearly define both Pax4 and Arx as master regulators of β-cell regeneration through the 
concerted processes of trans-differentiation, neogenesis and replication.  
 
c. Pax4 and Arx as ‘druggable’ targets: Reality or fiction 
 
The next challenge is now to seek naturally occurring or chemical factors which temporally 
induced Pax4 expression or repress Arx levels in order to promote regeneration within the 
autoimmune environment. Recently Dirice and colleagues reported that soluble factors such 
as IL-2, -6 and 10 secreted by invading immune T-cells stimulated β-cell regeneration 
172
. 
Whether these cytokines have an impact on either Pax4 or Arx expression remains to be 
established. Glucagon-like peptide-1 (GLP-1) was also proposed to potentially promote α- to β-
cell trans-differentiation through activation of Pax4 
173
. The feasibility of targeting transcription 
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factors with small therapeutic molecules was recently validated for the islet-enriched 
transcription factor Pdx1 
174
. These exciting results open a new era towards a potential 
regenerative therapy for the treatment of T1DM by targeting transcription factors such as 
Pax4 and Arx. 
 
 
6. Expert Opinion 
 
The last 15 years have witnessed different strategies to obtain insulin-producing cells from 
stem cells. Since the pioneer “proof-of-concept” with mouse embryonic stem cells it was 
crystal clear that developmental biology-based approaches were instrumental in the challenge 
of making a pancreatic β-cells. ViaCyte Inc. group succeeded in translating mouse knowledge 
into human embryonic stem cells. Whilst recently several groups, including ours, have came 
out with new strategies to generate functional β-cells from human stem cells, ViaCyte Inc. took 
a step ahead and start a clinical trial with 4 diabetic patients transplanted with pancreatic 
progenitors derived from stem cells. The maturation of pancreatic progenitors are expected 
inside the ViaCyte device implanted in patient’s body, which could be very promising in the 
finding of a cure for type 1 diabetic people. Undoubtedly the recent events prelude the 
beginning of a new era in diabetes therapy. In spite of that, in our opinion there are still so 
many unanswered questions. While the generation of pancreatic progenitors from stem cells 
seems to be easier to accomplish than obtaining glucose-responding and insulin-producing 
cells, should we then focus in the in the β-cell maturation process? Are the pancreatic β-cells 
interconnected with other non-β endocrine cells, and if so, should we generate whole islets 
from stem cells? Should they be vascularized? Could we find a “miraculous” small molecule or 
cellular treatment that promote β-cells regeneration? Would cell-selection be needed to avoid 
remaining non-differentiated cells? Would these cells be tolerated by immune system? 
 
Successful projects on making β-cells from stem cells have been funded by public systems in 
Europe and USA. However, it is a private company who is taking the control of such success, 
Johnson & Johnson Group. In order to get the best cost-effective treatment so every diabetic 
person could benefit of the in vitro generated β-cells, we think that the combination of private 
and public systems should control the production with its risks and benefits. That will 
definitively accelerate the process. We keep the hope that a century after the discovery of 
insulin we are now close to a cure for diabetes rather than for new treatment. 
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Figure legends 
 
Figure 1. From Embryonic Stem Cells to Insulin Producing cells: a summary of progress. 
Schematic representation of the contributors to the development of differentiation strategies 
to generate insulin producing cells from mouse and human pluripotent cells. ViaCyte Inc. 
signed rights agreement with Janssen Research & Development LLC. BetaLogics is a subsidiary 
of Janssen Research & Development LLC a Pharmaceutical company of the Johnson & Johnson 
Group. Contributions identified by the first author (see Reference section) 
 
Figure 2. The Challenge of making a β-cell: A. Simplified scheme of glucose-sensing 
mechanism, exocytotic machinery and gene expression, processing and storage of insulin. G: 
Glucose; Glut-2: Glucose transporter; GK: Glucokinase; G-6-P: glucose-6-phosphate; ATP: 
adenosinetriphosphate, DPs: diadenosinepolyphosphates; KATP: ATP-regulated potassium 
channels; T. Factors: transcription factors. B. Intraperitoneal glucose-tolerance test in 
overnight fasted non-diabetic mice (o) and in streptozotocin-diabetic mice transplanted with 
insulin-producing cells under the kidney capsule (taken from: Vaca P. et al. Stem Cells 2006; 
24:258-265). C. Blood glucose after transplantation of insulin producing cells under the kidney 
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capsule. TX: Transplantation; GR: graft removal (from León-Quinto T. et al. Diabetologia 2004; 
47:1442-1451). D. Dose-dependent effect on blood glucose. (o) Control STZ-diabetic mice; (∆) 
Transplanted with 1 x 10
6
 cells or with (•) 5 x 10
6
 cells under the kidney capsule (from Roche E. 
et al. Handb Exp Pharmacol 2006; 174:147-167). E. Blockade of ATP-dependent K currents by 
ATP. Inside-out patch recoding at membrane potential = 0 mV (taken from Vaca P. et al. Stem 
Cells 2006; 24:258-265). F. Graft removed 3 weeks after transplantation removal (from León-
Quinto T. et al. Diabetologia 2004; 47:1442-1451). 
 
Figure 3. Summary of Pancreas Organogenesis and Differentiation and Maturation strategies 
to obtain a β-cell fate. Protocol Stages: ESC: embryonic stem cells; iPS: induced pluripotent 
cells; ME: mesendoderm; DE: definitive endoderm; PG: primitive gut; PF: posterior foregut; PE: 
pancreatic endoderm; EP: endocrine precursors. Transcription Factors and Signaling Pathways: 
FoxA2: Forkhead box A2; GATA4: GATA binding protein 4; Sox17: SRY (sex determining region 
Y)-box 17; PDX1: Pancreatic and duodenal homeobox 1; PTF1a: pancreas specific transcription 
factor 1a; Nkx2.2: NK2 homeobox 2; Sox9: SRY (sex determining region Y)-box 9; Ngn3: 
Neurogenin 3; NeuroD: Neuronal differentiation; MafA: V-maf avian musculoaponeurotic 
fibrosarcoma oncogene homolog A; Wnt: Wnt signaling pathway; PI3K: Phosphatidylinositol-
4,5-bisphosphate 3-kinase; Shh: sonic hedgehog. Soluble Factors and culture media inducing in-
vitro differentiation: FBS: fetal bovine serum; Wnt3a: Wingless-type MMTV integration site 
family, member 3A; Sirt-1: Sirtuin 1; bFGF: Basic fibroblast growth factor; RA: retinoic acid; ITS: 
insulin-transferrin-selenium. New Factors: R288: small-molecule inhibitor of the tyrosine kinase 
receptor AXL; Alk5i: Alk5 receptor inhibitor; T3: thyroid hormone T3; N-Cys: N-acetyl cysteine. 
Potential factors: Reg-1: regenerating islet-derived 1; mir7: mir-7 microRNA precursor; mir375: 
miR-375 microRNA. 
 
Figure 4. Effect of late maturation on hESCs-derived insulin-secreting cells. Upper: In-vitro 
staining for human C-peptide and insulin in hESC-derived insulin containing cells which 
followed a conventional protocol. Lower: hESC-derived cells exposed to late maturation factors. 
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Figure 1. Schematic representation of the contributors to the development of differentiation strategies to 
generate insulin-producing cells from mouse and human pluripotent cells.  
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Figure 2. Pancreatic β-cell: A representation of glucose-sensing mechanism, exocytotic machinery and gene 
expression, processing and storage of insulin.  
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Figure 3. Pancreas organogenesis summary, differentiation strategies and maturation processes used to 
obtain a β-cell fate.  
 
hESC, human embryonic stem cells; iPS: induced pluripotent cells; ME, mesendoderm; DE, definitive 
endoderm; PG, primitive gut; PF, posterior foregut; PE, pancreatic endoderm; EP, endocrine precursors; RA, 
retinoic acid; ITS, insulin-transferrin-selenium; R288, small-molecule inhibitor of the tyrosine kinase 
receptor AXL; Alk5i, Alk5 receptor inhibitor; T3, thyroid hormone T3; N-Cys, N-acetyl cysteine.  
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Figure 4. Maturation promotes hESCs-derived insulin-secreting cells obtention.  
178x104mm (300 x 300 DPI)  
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4. Insulin and C-peptide content  + + + 
 
5. Stimulus-secretion coupling (Glucose-induced insulin release) 
[Ca
2+
]i  signals 
 
Glucose-induced insulin release 
 
In-vitro 
Basal vs Stimulated 
Depolarization-induced 
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In vivo 
Human C-peptide/insulin 
Glucose challenge  
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6. Blood glucose normalization 
Rodent models 
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7. Preclinical Studies 
In vivo maturation 
GLP studies 
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